Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.
about
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsRapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosisPredicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutationsCorrelation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility resultsQuantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance EscalationA Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, RussiaRoutine use of microbial whole genome sequencing in diagnostic and public health microbiologyComparison of TaqMan(®) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB.Simplified microarray system for simultaneously detecting rifampin, isoniazid, ethambutol, and streptomycin resistance markers in Mycobacterium tuberculosisConcordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United StatesEffects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Comparison of Three Commercial Molecular Assays for Detection of Rifampin and Isoniazid Resistance among Mycobacterium tuberculosis Isolates in a High-HIV-Prevalence SettingRifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study.Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature codingPerformance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settingsImportance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistanceFalse-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load.Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Rifampin drug resistance tests for tuberculosis: challenging the gold standard.Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance.Genotypic Detection of rpoB and katG Gene Mutations Associated with Rifampicin and Isoniazid Resistance in Mycobacterium Tuberculosis Isolates: A Local Scenario (Kelantan).Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013.Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany.Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs.Mycobacterium diagnostics: from the primitive to the promising.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.Rifampicin Resistance: Fitness Costs and the Significance of Compensatory Evolution.Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations.Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.Frequency and Type of Disputed rpoB Mutations in Mycobacterium tuberculosis Isolates from South Korea.New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolatesAbsence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' Rifampicin mutations.Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact.Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania.
P2860
Q24200879-7210B59E-0005-4563-BB27-44712BAA553CQ24201466-45271BD6-8498-4C20-8CEE-86CF8DE44A13Q27342229-B0194DAF-C224-483A-B657-64DCB56522E9Q28397752-666E564F-9910-4759-9E53-E2205D80B29AQ28540488-3D115143-85A6-4A2B-BED4-5CBAB154628BQ28543642-6FA3F658-4941-45D1-AFB7-EE16E0CAE45EQ28547769-82FE279D-496B-435B-A736-624F6DBB72B8Q28554618-7F8451FE-C1FC-49BD-9709-F4F93C9773D8Q28728617-30E15742-B807-4D68-ABD0-F5E1C955989CQ30276393-CE6F2678-A64B-4167-B175-7DE231E54E17Q33703304-F806B7D9-CE9D-4B83-8F1C-ADB2C0FB480CQ33703407-863353F7-B1D5-463B-8436-C16D2D223249Q34076574-26DF0BDD-1C15-4AD3-BF2A-0455E7BDA758Q34298988-5F0CA2F2-A367-4A39-B9FF-607F2B65611EQ35169089-94B7BAE6-66D2-483A-87FC-3A0AED95DD82Q35968590-518142F7-0778-461A-9D0E-34377E9533FBQ36103146-3E087037-D462-4E0C-9A26-E5626E2E71A1Q36118693-8D898940-9325-4B4C-BE9A-FD9DFE494450Q36228816-65F1C733-7FAC-4BAA-B524-0267F862B5A1Q36396241-B63372A9-4FC9-4ECA-B5C4-745B6B0107C2Q36827305-A0192045-A778-40EB-A067-7C6BBD61C2B4Q36933441-3D6E6A77-C162-49EE-AA69-9F388DB09632Q37036190-5720DD83-5217-4360-B248-D08181132511Q37125148-28A7D2B3-F513-4B77-BA3D-3D72ED74109AQ37155860-99D424D1-CF98-4CD7-9CDF-FD4B7C2BF88FQ37305611-543FFC1E-A6A6-462F-8874-74A45780B62EQ37544490-7A3261E6-D5A4-4153-9EE2-841644CC1C49Q38059860-044ED0C0-84B5-46CE-BB25-22874CF82027Q38438695-483BCB22-5614-4026-9E07-02300F762EC7Q38502298-7E2DABCB-B803-497B-AC84-99D0607685BDQ38793891-4425DCFA-8613-429F-A2E2-74F8F1D1DE2EQ38839490-6BC58E89-FDDD-4A43-B140-083DDB978AF6Q38979626-E58CC7B5-4C91-442E-BC64-E7EBEF999C20Q39398953-52103627-2EBD-49BC-93B4-AAA3A7E1DED4Q41105755-E6A9504A-A7E1-491E-91E7-65C51D705262Q41124285-008CD503-C7A0-4B18-B9EA-90FF37B94133Q42693542-C4A070B3-F737-49B1-BFEC-197DEFA34296Q46669106-D945AACE-BB49-4F90-A7D6-A042E192B5FEQ50733068-775931E6-F462-4F45-A7FF-85BF09AC6174Q55424405-6EE36E06-FBBE-4656-8446-66A0448A2094
P2860
Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical failures associated w ...... nt Mycobacterium tuberculosis.
@en
Clinical failures associated w ...... nt Mycobacterium tuberculosis.
@nl
type
label
Clinical failures associated w ...... nt Mycobacterium tuberculosis.
@en
Clinical failures associated w ...... nt Mycobacterium tuberculosis.
@nl
prefLabel
Clinical failures associated w ...... nt Mycobacterium tuberculosis.
@en
Clinical failures associated w ...... nt Mycobacterium tuberculosis.
@nl
P2093
P356
P1476
Clinical failures associated w ...... ant Mycobacterium tuberculosis
@en
P2093
J T Freeman
S A Roberts
P304
P356
10.5588/IJTLD.11.0178
P577
2012-02-01T00:00:00Z